Pharmacologic approaches to the treatment of Huntington's disease

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 31-41

  Venuto, Charles S ^a,b   Mcgarry, Andrew ^a   Ma, Qing ^a,b   Kieburtz, Karl ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Behavioral; Chorea; Cognitive; Disease modifying; Huntington; Hyperkinetic; Therapeutics; Treatment

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; CLOZAPINE; DIMEBON; DONEPEZIL; ETHYL EICOSAPENTAENOIC ACID; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; KETAMINE; MEMANTINE; MILACEMIDE; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PAROXETINE; PIMOZIDE; PRIDOPIDINE; QUETIAPINE; REMACEMIDE; RILUZOLE; RISPERIDONE; RIVASTIGMINE; TETRABENAZINE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AKATHISIA; ALZHEIMER DISEASE; ANXIETY DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WALKING DIFFICULTY;

ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; DOPAMINE ANTAGONISTS; DRUG THERAPY; FATTY ACIDS, OMEGA-3; HUMANS; HUNTINGTON DISEASE; MOVEMENT DISORDERS; NEUROPROTECTIVE AGENTS;

EID: 84855922033     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23953     Document Type: Review

References (131)

1. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006; 12: 2701-2710.
2. Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 2007; 8: 141-153.
3. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem 1986; 47: 331-339.
4. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959; 127: 103-109.
5. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982; 12: 257-262.
6. Henry JP, Botton D, Sagne C, et al. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J Exp Biol 1994; 196: 251-262.
7. Xenazine (tetrabenazine) package insert. Deerfield, IL: Lundbeck, Inc; September 2009.
8. Schreiver W, Krieg JC. Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition [Letter]. J Neurol Neurosurg Psychiatry 1999; 67: 550.
9. Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J Pharmacol 1984; 102: 431-436.
10. Lende N. Psychosedative effects of tetrabenazine (RO 1-9569) on hyperactive and disturbed mentally retarded patients. Dis Nerv Syst 1960; 21( 3 Suppl): 118-119.
11. Kanjilal GC, Matheson B. A trial of tetrabenazine ("Nitoman") in disturbed mentally subnormal patients. J Ment Sci 1962; 108: 225-228.
12. Moller-Christensen B, Videbech T. Treatment of Huntington's chorea with tetrabenazine (Nitoman). Ugeskr Laeger 1963; 125: 207-209.
13. Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007; 22: 10-13.
14. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66: 366-372.
15. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 2009; 9: 62.
16. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22: 193-197.
17. Frank S, Ondo W, Fahn S, et al. A study of chorea after teterabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008; 31: 127-133.
18. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8: 323-333.
19. Poon LH. Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother 2010; 44: 1080-1089.
20. Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology 1985; 35: 1450-1454.
21. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988; 38: 84-88.
22. Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 1984; 47: 848-852.
23. Caraceni T, Giovannini P, Girotti F, Avanzini G. Pharmacology of Huntington's chorea. Personal experience. Eur Neurol 1977; 16: 42-50.
24. Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989; 4: 282-287.
25. Terrence CF. Fluphenazine decanoate in the treatment of chorea: a double-blind study. Curr Ther Res Clin Exp 1976; 20: 177-183.
26. Whittier JR, Korenyi C. Effect of oral fluphenazine on Huntington's chorea. Int J Neuropsychiatry 1968; 4: 1-3.
27. Korenyi C, Whittier JR. Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin). Psychiatr Q 1967; 41: 203-210.
28. Arena R, Iudice A, Virgili P, Moretti P, Menchetti G. Huntington's disease: clinical effects of a short-term treatment with pimozide. Adv Biochem Psychopharmacol 1980; 24: 573-575.
29. Siegmund R, Schmeisser G, Heidrich R. Therapeutic experiences in the treatment of hyperkineses with the neuroleptic pimozide (Antalon, Orap) in the frame of Huntington chorea. Psychiatr Neurol Med Psychol (Leipz) 1982; 34: 307-308.
30. McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study. N Z Med J 1976; 83: 114-116.
31. Bischoff S, Bittiger H, Delini-Stula A, Ortmann R. Septo-hippocampal system: target for substituted benzamides. Eur J Pharmacol 1982; 79: 225-232.
32. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984; 9: 329-338.
33. Chouza C, Romero S, Lorenzo J, et al. [Clinical trial of tiapride in patients with dyskinesia (author's transl)]. Sem Hop 1982; 58: 725-733. [French]
34. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984; 47: 844-847.
35. Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study. J Psychopharmacol 1996; 10: 162-165.
36. Reveley MA, Dursun SM, Andrews H. Improvement of abnormal saccadic eye movements in Huntington's disease by sulpiride: a case study. J Psychopharmacol 1994; 8: 262-265.
37. Assistance Publique-Hopitaux de Paris. Neuroleptic and Huntington Disease Comparison of: olanzapine, la tetrabenazine and tiapride (NEUROHD). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00632645. Available at: Accessed August 19, 2011.
38. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol 2002; 25: 263-265.
39. Bonelli RM, Mayr BM, Niederwieser G, Reisecker F, Kapfhammer HP. Ziprasidone in Huntington's disease: the first case reports. J Psychopharmacol 2003; 17: 459-460.
40. Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011; 26: 147-152.
41. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136: 317-320.
42. Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A. Clozapine in Huntington's chorea. Neurology 1994; 44: 821-823.
43. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63: 35-39.
44. Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 69-72.
45. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002; 105: 441-444.
46. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003; 37: 687-694.
47. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009; 24: 126-129.
48. Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. Am J Psychiatry 2008; 165: 1207-1208.
49. Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat 2009; 5: 1-4.
50. Oulis P, Mourikis I, Konstantakopoulos G, Papageorgiou SG, Kouzoupis AV. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease. J Neuropsychiatry Clin Neurosci 2010; 22: 352c.e4-352.e5.
51. Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol 1997; 17: 134-135.
52. Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999; 19: 101-103.
53. Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol 2002; 249: 1114-1115.
54. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol 2010; 33: 260-264.
55. NeuroSearch. NeuroSearch A/S - Company Announcement. NeuroSearch A/S announces the results of additional assessment and analysis of data from the Phase III MermaiHD study with Huntexil® in Huntington's disease. 2010 News Releases. Published: 2010-04-28 09:43:26 CEST. Available at: Accessed August 19, 2011.
56. McGarry A, Kieburtz K, Rembratt A, Tedroff J, Huntington Study Group HART Investigators. A randomized, double-blind placebo-controlled trial of ACR16 in Huntington's Disease. Poster session presented at: Huntington Study Group Meeting, 4th Annual Huntington Disease Clinical Research Symposium; October 16, 2010, La Jolla, CA. Rochester, NY: Huntington Study Group.
57. Kieburtz K. Open-label extension study of pridopidine (ACR16) in the symptomatic treatment of Huntington disease (OPEN-HART). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT01306929. Available at: Accessed August 19, 2011.
58. Murman DL, Giordani B, Mellow AM, et al. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 1997; 49: 153-161.
59. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003; 61: 1551-1556.
60. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007; 62: 262-272.
61. Giuffra ME, Mouradian MM, Chase TN. Glutamatergic therapy of Huntington's chorea. Clin Neuropharmacol 1992; 15: 148-151.
62. Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002; 59: 694-699.
63. Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003; 60: 1995-1997.
64. O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003; 60: 996-998.
65. Heckmann JM, Legg P, Sklar D, Fine J, Bryer A, Kies B. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2004; 63: 597-598.
66. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007; 13: 453-454.
67. Lipton S. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004; 1: 101-110.
68. Corey-Bloom J. Study of memantine to treat Huntington's disease. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00652457. Available at: Accessed August 19, 2011.
69. Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002; 13: 29-33.
70. Puri BK, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002; 13: 123-126.
71. Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann CF. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. J Int Med Res 2008; 36: 896-905.
72. Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65: 286-292.
73. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65: 1582-1589.
74. Smith R, Chung H, Rundquist S, et al. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet 2006; 15: 3119-3131.
75. Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD. Brain muscarinic cholinergic receptors in Huntington's disease. J Neurol 1992; 239: 103-104.
76. Wastek GJ, Stern LZ, Johnson PC, Yamamura HI. Huntington's disease: regional alteration in muscarinic cholinergic receptor binding in human brain. Life Sci 1976; 19: 1033-1039.
77. Kumar P, Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol 2009; 615: 91-101.
78. Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the treatment of Huntington's disease. Eur J Neurol 2002; 9: 689-690.
79. de Tommaso M, Specchio N, Sciruicchio V, Difuscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord 2004; 19: 1516-1518.
80. de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol 2007; 30: 43-46.
81. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142.
82. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord 2000; 15: 173-176.
83. Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006; 67: 1268-1271.
84. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001; 939: 425-435.
85. Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003; 136: 474-477.
86. Lermontova NN, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000; 129: 544-546.
87. Giorgetti M, Gibbons JA, Bernales S, et al. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther 2010; 333: 748-757.
88. Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 2010; 21: 389-402.
89. Bernales SW, Protter SA, Hung DT. Dimebon includes neurite outgrowth and mitochondrial stabilization. In: Proceedings of the Society for Neuroscience Annual Meeting, November 15-19, 2008; Washington, DC. Washington, DC: Society of Neuroscience; 2008.
90. Kieburtz K, McDermott MP, Voss TS, et al.; Huntington Disease Study Group DIMOND Investigators. Arch Neurol 2010; 67: 154-160.
91. Leroi I, Michalon M. Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. Can J Psychiatry 1998; 43: 933-940.
92. Rosenblatt A. Neuropsychiatry of Huntington's disease. Dialogues Clin Neurosci 2007; 9: 191-197.
93. Como PG, Rubin AJ, O'Brien CF, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 1997; 12: 397-401.
94. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol 2009; 29: 484-487.
95. Beglinger LJ, Fiedorowicz JG, Biglan K, Caviness J, Jorge R. CIT-HD: study in Huntington's disease. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00271596. Available at: Accessed August 19, 2011.
96. Holl AK, Wilkinson L, Painold A, Holl EM, Bonelli RM. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 2010; 25: 46-50.
97. Rilutek (riluzole) package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; August 2009.
98. Guyot MC, Palfi S, Stutzmann JM, Maziere M, Hantraye P, Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 1997; 81: 141-149.
99. Palfi S, Riche D, Brouillet E, et al. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp Neurol 1997; 146: 135-141.
100. Mary V, Wahl F, Stutzmann JM. Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 1995; 201: 92-96.
101. Katoh-Semba R, Asano T, Ueda H, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in rat hippocampus. FASEB J 2002; 16: 1328-1330.
102. Ciammola A, Sassone J, Cannella M, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 574-577.
103. Squitieri F, Ciammola A, Colonnese C, Ciarmiello A. Neuroprotective effects of riluzole in Huntington's disease. Eur J Nucl Med Mol Imaging 2008; 35: 221-222.
104. Squitieri F, Orobello S, Cannella M, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 2009; 36: 1113-1120.
105. Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatri Dis Treat 2009; 5: 597-610.
106. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997; 41( 2): 160-165.
107. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57( 3): 397-404.
108. Cudkowicz M, McDermott M, Kieburtz K. Coenzyme Q10 in Huntington's Disease (HD). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00608881. Available at: Accessed August 19, 2011.
109. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000; 20: 4389-4397.
110. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001; 8: 479-491.
111. Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003; 61: 141-142.
112. Tabrizi SJ, Blamire AM, Manners DN, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005; 64: 1655-1656.
113. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006; 66: 250-252.
114. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003; 61: 925-930.
115. Hersch SM, Schifitto G, Rosas D. Creatine safety, tolerability, and efficacy in Huntington's disease (CREST-E). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00712426. Available at: Accessed August 19, 2011.
116. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5825.
117. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntington shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 2005; 12: 618-633.
118. Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 2005; 53: 241-249.
119. Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 2008; 16: 947-956.
120. Harper SQ. Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 2009; 66: 933-938.
121. Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000; 356: 1975-1979.
122. Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006; 5: 303-309.
123. Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002; 58: 687-695.
124. Cicchetti F, Saporta S, Hauser RA, et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 2009; 106: 12483-12488.
125. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998; 149: 97-108.
126. Philpott LM, Kopyov OV, Lee AJ, et al. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 1997; 6: 203-212.
127. Quinn N, Brown R, Craufurd D, et al. Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov Disord 1996; 11: 143-150.
128. Assistance Publique-Hopitaux de Paris. MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. ClinicalTrials.gov identifier: NCT00190450. Available at: Accessed August 19, 2011.
129. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opinion Neurol 2008; 21: 497-503.
130. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009; 8: CD006455.
131. Ramaswamy S, Shannon KM, Kordower JH. Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant 2007; 16: 301-312.